ALDX
Aldeyra Therapeutics, Inc.
1.30$
-3.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +221.0% | -10.7% | +75.4% | +115.3% | -20.6% | +10.4% | +179.7% | -22.2% | -18.2% | -29.5% | -31.1% | |
| – | +220.6% | -10.5% | +74.9% | +115.6% | -20.7% | +10.5% | +180.2% | -22.2% | -18.3% | -29.6% | -31.0% | |
| – | +71.8% | -18.0% | +66.7% | +136.5% | -6.2% | +75.3% | +195.1% | -37.2% | -1.1% | -61.8% | +28.5% | |
| – | +223.6% | -9.7% | +72.4% | +117.9% | -21.6% | +6.1% | +195.1% | -24.1% | -18.1% | -29.2% | -30.8% | |
| – | – | – | – | +144.4% | -36.4% | -10.7% | -99.9% | +11,168.8% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +518.0% | -29.9% | -23.2% | +443.7% | -36.9% | -59.6% | -45.8% | -40.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +32.9% | +6.4% | +29.3% | +85.2% | +223.8% | -13.1% | +14.9% | +10.5% | -5.8% | +17.8% | -17.2% | |
| – | +59.3% | +8.7% | +45.9% | +152.6% | +52.3% | -3.9% | -5.1% | +30.5% | +44.9% | -16.4% | +49.5% | |
| – | +0.0% | +0.0% | +50.0% | – | – | +1,620.1% | -94.1% | +405.7% | +1,225.2% | -98.0% | +5,025.4% | |
| – | +149.4% | -67.6% | +263.4% | +204.9% | -73.5% | -52.8% | +167.2% | -86.9% | +901.4% | -86.5% | -12.2% | |
| – | +3.1% | +2.3% | -1.5% | – | – | -21.3% | +35.6% | -3.7% | – | – | – | |
| – | +295.9% | -13.0% | +82.9% | +118.7% | -44.5% | +23.8% | +245.7% | -26.6% | -20.7% | -40.7% | -37.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +124.2% | +31.5% | +40.3% | +36.2% | +25.0% | +25.3% | +59.1% | +8.1% | +0.9% | +0.9% | +1.0% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.